Fenaille François, Groseil Catherine, Ramon Christine, Riandé Sandrine, Siret Laurent, Chtourou Sami, Bihoreau Nicolas
Laboratoire Français du Fractionnement et des Biotechnologies, 3 avenue des Tropiques, BP 305, Les Ulis, 91958, Courtaboeuf cedex, France.
Glycoconj J. 2008 Dec;25(9):827-42. doi: 10.1007/s10719-008-9143-7. Epub 2008 Jul 20.
Factor VII (FVII) is a vitamin K-dependent glycoprotein which, in its activated form (FVIIa), participates in the coagulation process by activating factor X and factor IX. FVII is secreted as single peptide chain of 406 residues. Plasma-derived FVII undergoes many post-translational modifications such as gamma-carboxylation, N- and O-glycosylation, beta-hydroxylation. Despite glycosylation of recombinant FVIIa has been fully characterized, nothing is reported on the N- and O-glycans of plasma-derived FVII (pd-FVII) and on their structural heterogeneity at each glycosylation site. N- and O-glycosylation sites and site specific heterogeneity of pd-FVII were studied by various complementary qualitative and quantitative techniques. A MALDI-MS analysis of the native protein indicated that FVII is a 50.1 kDa glycoprotein modified on two sites by diantennary, disialylated non-fucosylated (A2S2) glycans. LC-ESIMS/MS analysis revealed that both light chain and heavy chain were N-glycosylated mainly by A2S2 but also by triantennary sialylated glycans. Nevertheless, lower amounts of triantennary structures were found on Asn(322) compared to Asn(145). Moreover, the triantennary glycans were shown to be fucosylated. In parallel, quantitative analysis of the isolated glycans by capillary electrophoresis indicated that the diantennary structures represented about 50% of the total glycan content. Glycan sequencing using different glycanases led to the identification of triantennary difucosylated structures. Last, MS and MS/MS analysis revealed that FVII is O-glycosylated on the light chain at position Ser(60) and Ser(52) which are modified by oligosaccharide structures such as fucose and Glc(Xyl)(0-1-2), respectively. These latter three O-glycans coexist in equal amounts in plasma-derived FVII.
凝血因子 VII(FVII)是一种维生素 K 依赖的糖蛋白,其活化形式(FVIIa)通过激活因子 X 和因子 IX 参与凝血过程。FVII 以 406 个残基的单肽链形式分泌。血浆来源的 FVII 经历许多翻译后修饰,如γ-羧化、N-和 O-糖基化、β-羟基化。尽管重组 FVIIa 的糖基化已得到充分表征,但关于血浆来源的 FVII(pd-FVII)的 N-和 O-聚糖及其在每个糖基化位点的结构异质性尚无报道。通过各种互补的定性和定量技术研究了 pd-FVII 的 N-和 O-糖基化位点以及位点特异性异质性。对天然蛋白的基质辅助激光解吸电离质谱(MALDI-MS)分析表明,FVII 是一种 50.1 kDa 的糖蛋白,在两个位点被二天线、双唾液酸化、非岩藻糖基化(A2S2)聚糖修饰。液相色谱-电喷雾电离串联质谱(LC-ESIMS/MS)分析表明,轻链和重链均主要被 A2S2 糖基化,但也被三天线唾液酸化聚糖糖基化。然而,与天冬酰胺(Asn)145 相比,在天冬酰胺(Asn)322 上发现的三天线结构数量较少。此外,三天线聚糖显示被岩藻糖基化。同时,通过毛细管电泳对分离出的聚糖进行定量分析表明,二天线结构约占总聚糖含量的 50%。使用不同糖苷酶进行聚糖测序可鉴定出三天线二岩藻糖基化结构。最后,质谱和串联质谱分析表明,FVII 在轻链的丝氨酸(Ser)60 和丝氨酸(Ser)52 位点发生 O-糖基化,分别被岩藻糖和 Glc(Xyl)(0-1-2)等寡糖结构修饰。后三种 O-聚糖在血浆来源的 FVII 中以等量共存。